US 12,297,219 B2
Phosphorodiamidate morpholino oligomers
Baozhong Cai, Cambridge, MA (US); Mitchell Martini, Cambridge, MA (US); Katie Thomas, Cambridge, MA (US); and Ross Shimabuku, Cambridge, MA (US)
Assigned to Sarepta Therapeutics, Inc., Cambridge, MA (US)
Filed by Sarepta Therapeutics, Inc., Cambridge, MA (US)
Filed on Jun. 15, 2022, as Appl. No. 17/841,185.
Application 17/841,185 is a continuation of application No. 16/302,529, granted, now 11,472,824, previously published as PCT/US2017/040318, filed on Jun. 30, 2017.
Claims priority of provisional application 62/508,256, filed on May 18, 2017.
Claims priority of provisional application 62/357,166, filed on Jun. 30, 2016.
Claims priority of provisional application 62/357,134, filed on Jun. 30, 2016.
Claims priority of provisional application 62/341,049, filed on May 24, 2016.
Claims priority of provisional application 62/340,953, filed on May 24, 2016.
Prior Publication US 2023/0045831 A1, Feb. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/11 (2006.01); C07F 9/6512 (2006.01); C07F 9/6533 (2006.01); C07F 9/6558 (2006.01); C07F 9/6561 (2006.01); C12N 15/113 (2010.01)
CPC C07F 9/6533 (2013.01) [C07F 9/6512 (2013.01); C07F 9/65583 (2013.01); C07F 9/65616 (2013.01); C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/314 (2013.01); C12N 2310/3233 (2013.01); C12N 2310/51 (2013.01)] 2 Claims
 
1. A compound of Formula (X):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
R1 is a support-medium, and
R2 is, independently at each occurrence, selected from the group consisting of:

OG Complex Work Unit Chemistry
 and
wherein R2 is at each position from 1 to 25 and 5′ to 3′:
 
Position No. 5′ to 3′ R2
 
 
1 DPG
2 T
3 T
4 DPG
5 PC
6 PC
7 T
8 PC
9 PC
10 DPG
11 DPG
12 T
13 T
14 PC
15 T
16 DPG
17 PA
18 PA
19 DPG
20 DPG
21 T
22 DPG
23 T
24 T
25 PC.